IL17A and chronic obstructive pulmonary disease: A lot of research has to be done before possible new drugs for COPD encompassing modulators of TLRs, chemokine receptor antagonists, protease inhibitors, and anticytokine (e.g., anti-IL-17, anti-IL-18) targeted therapies are available.